Comparative data on safety and efficacy of new generation drug-eluting stents (DESs) are still lacking, the objective of this study is to compare the safety and efficacy of commonly used DESs in patients with coronary artery disease (CAD). Individual data of 146 consecutive patients (119 Male and 27 Female) stented with different DESs such as Sirolimus (SESs), Everolimus (EESs) or Zotarolimus (ZESs) eluting stents was randomly collected from various hospitals in South India. Pooled data was retro-prospectively analysed, the primary end-point of this study was determination of major adverse cardiovascular events (MACE) and individual events, which is a composite of cardiac death, target vessel related myocardial infarction (TV-MI), target lesion revascularization (TLR), target vessel revascularization (TVR), stent thrombosis (ST) and in-stent restenosis (ISR) at the end of clinical follow-up which was scheduled at three months once up to one-year after angioplasty. Baseline clinical and cardiac characteristics, angiographic and stent procedural characteristics, efficacy and suspected adverse reactions were compared. Our study results indicates that SESs (a first-generation DES) were found to be non-inferior to EESs and ZESs in reducing risks and remains safe and effective at the end of one-year clinical follow- up period in CAD patients after angioplasty.
Key words: Angioplasty, Coronary artery disease, Drug eluting stents, Everolimus, Sirolimus, Safety and efficacy.
|
